Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 May;77(5):1632–1638. doi: 10.1172/JCI112480

Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy.

A S Lau, G E Hannigan, M H Freedman, B R Williams
PMCID: PMC424568  PMID: 3009549

Abstract

Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. The binding characteristics of IFN to human lymphocytes were studied using IFN alpha 2 labeled with 125I to high specific activity. The specific binding curves generated were analyzed by the LIGAND program of Munson and Rodbard to determine receptor numbers. The number of receptors in peripheral blood lymphocytes (PBL) and tonsillar B-lymphocytes (TBL) from normal individuals were 505 +/- 293 (n = 10) and 393 +/- 147 (n = 3) respectively. When these cells were preincubated in vitro with unlabeled IFN alpha 2, the receptor number decreased to 82 +/- 45 and 61 +/- 16 respectively. Receptor binding activities recovered gradually over a period of 72 h when the cells were incubated in IFN-free medium. This recovery of receptors could be blocked by the addition of actinomycin D to the incubation medium. A similar decrease in receptor expression was observed in vivo in PBL from patients being treated daily with 5 X 10(6) units/m2 per d of IFN alpha 2 by subcutaneous injection, for acute lymphoblastic leukemia or papilloma virus infections. Receptor numbers in PBL in vivo were further reduced concurrent with the progression of IFN therapy. Thus the reduction in IFN receptor expression observed in vitro can be demonstrated in vivo. These studies indicate that monitoring IFN receptor expression in vivo can provide information regarding the availability of IFN receptors at the cell surface for the mediation of IFN actions during the course of IFN therapy.

Full text

PDF
1632

Images in this article

1635Image
on p.1635
1636Image
on p.1636

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Yip Y. K., Vilcek J. Human interferon-gamma is internalized and degraded by cultured fibroblasts. J Biol Chem. 1983 May 25;258(10):6497–6502. [PubMed] [Google Scholar]
  2. Branca A. A., Baglioni C. Down-regulation of the interferon receptor. J Biol Chem. 1982 Nov 25;257(22):13197–13200. [PubMed] [Google Scholar]
  3. Branca A. A., Baglioni C. Evidence that types I and II interferons have different receptors. Nature. 1981 Dec 24;294(5843):768–770. doi: 10.1038/294768a0. [DOI] [PubMed] [Google Scholar]
  4. Branca A. A., Faltynek C. R., D'Alessandro S. B., Baglioni C. Interaction of interferon with cellular receptors. Internalization and degradation of cell-bound interferon. J Biol Chem. 1982 Nov 25;257(22):13291–13296. [PubMed] [Google Scholar]
  5. Carpenter G., Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193–216. doi: 10.1146/annurev.bi.48.070179.001205. [DOI] [PubMed] [Google Scholar]
  6. Cesario T. C. The clinical implications of human interferon. Med Clin North Am. 1983 Sep;67(5):1147–1162. doi: 10.1016/s0025-7125(16)31171-3. [DOI] [PubMed] [Google Scholar]
  7. Chany C., Vignal M. Effect of prolonged interferon treatment on mouse embryonic fibroblasts transformed by murine sarcoma virus. J Gen Virol. 1970 Jun;7(3):203–210. doi: 10.1099/0022-1317-7-3-203. [DOI] [PubMed] [Google Scholar]
  8. Dahlquist F. W. The meaning of Scatchard and Hill plots. Methods Enzymol. 1978;48:270–299. doi: 10.1016/s0076-6879(78)48015-2. [DOI] [PubMed] [Google Scholar]
  9. Desmyter J., De Groote J., Desmet V. J., Billiau A., Ray M. B., Bradburne A. F., Edy V. G., De Somer P. Administration of human fibroblast interferon in chronic hepatitis-B infection. Lancet. 1976 Sep 25;2(7987):645–647. doi: 10.1016/s0140-6736(76)92460-0. [DOI] [PubMed] [Google Scholar]
  10. Einhorn S., Blomgren H., Strander H. Interferon and spontaneous cytotoxicity in man. V. Enhancement of spontaneous cytotoxicity in patients receiving human leukocyte interferon. Int J Cancer. 1980 Oct 15;26(4):419–428. doi: 10.1002/ijc.2910260406. [DOI] [PubMed] [Google Scholar]
  11. Faltynek C. R., Branca A. A., McCandless S., Baglioni C. Characterization of an interferon receptor on human lymphoblastoid cells. Proc Natl Acad Sci U S A. 1983 Jun;80(11):3269–3273. doi: 10.1073/pnas.80.11.3269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Golub S. H., D'Amore P., Rainey M. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity. J Natl Cancer Inst. 1982 May;68(5):711–717. [PubMed] [Google Scholar]
  13. Gordon D. S., Jones B. M., Browning S. W., Spira T. J., Lawrence D. N. Persistent polyclonal lymphocytosis of B lymphocytes. N Engl J Med. 1982 Jul 22;307(4):232–236. doi: 10.1056/NEJM198207223070407. [DOI] [PubMed] [Google Scholar]
  14. Greenberg H. B., Pollard R. B., Lutwick L. I., Gregory P. B., Robinson W. S., Merigan T. C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976 Sep 2;295(10):517–522. doi: 10.1056/NEJM197609022951001. [DOI] [PubMed] [Google Scholar]
  15. Gupta S. L., Rubin B. Y., Holmes S. L. Regulation of interferon action in human fibroblasts: transient induction of specific proteins and amplification of the antiviral response by antinomycin D. Virology. 1981 Jun;111(2):331–340. doi: 10.1016/0042-6822(81)90337-8. [DOI] [PubMed] [Google Scholar]
  16. Haglund S., Lundquist P. G., Cantell K., Strander H. Interferon therapy in juvenile laryngeal papillomatosis. Arch Otolaryngol. 1981 Jun;107(6):327–332. doi: 10.1001/archotol.1981.00790420001001. [DOI] [PubMed] [Google Scholar]
  17. Hannigan G. E., Fish E. N., Williams B. R. Modulation of human interferon-alpha receptor expression by human interferon-gamma. J Biol Chem. 1984 Jul 10;259(13):8084–8086. [PubMed] [Google Scholar]
  18. Hannigan G. E., Gewert D. R., Fish E. N., Read S. E., Williams B. R. Differential binding of human interferon-alpha subtypes to receptors on lymphoblastoid cells. Biochem Biophys Res Commun. 1983 Jan 27;110(2):537–544. doi: 10.1016/0006-291x(83)91183-x. [DOI] [PubMed] [Google Scholar]
  19. Hannigan G. E., Gewert D. R., Williams B. R. Characterization and regulation of alpha-interferon receptor expression in interferon-sensitive and -resistant human lymphoblastoid cells. J Biol Chem. 1984 Aug 10;259(15):9456–9460. [PubMed] [Google Scholar]
  20. Merigan T. C., Rand K. H., Pollard R. B., Abdallah P. S., Jordan G. W., Fried R. P. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med. 1978 May 4;298(18):981–987. doi: 10.1056/NEJM197805042981801. [DOI] [PubMed] [Google Scholar]
  21. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  22. Quesada J. R., Hersh E. M., Gutterman J. U. Biologic therapy of hairy cell leukemia. Semin Oncol. 1984 Dec;11(4 Suppl 2):507–510. [PubMed] [Google Scholar]
  23. Quesada J. R., Reuben J., Manning J. T., Hersh E. M., Gutterman J. U. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984 Jan 5;310(1):15–18. doi: 10.1056/NEJM198401053100104. [DOI] [PubMed] [Google Scholar]
  24. Sarkar F. H., Gupta S. L. Interferon receptor interaction. Internalization of interferon alpha 2 and modulation of its receptor on human cells. Eur J Biochem. 1984 May 2;140(3):461–467. doi: 10.1111/j.1432-1033.1984.tb08125.x. [DOI] [PubMed] [Google Scholar]
  25. Sarkar F. H., Gupta S. L. Receptors for human gamma interferon: binding and crosslinking of 125I-labeled recombinant human gamma interferon to receptors on WISH cells. Proc Natl Acad Sci U S A. 1984 Aug;81(16):5160–5164. doi: 10.1073/pnas.81.16.5160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Standaert M. L., Pollet R. J. Equilibrium model for insulin-induced receptor down-regulation. Regulation of insulin receptors in differentiated BC3H-1 myocytes. J Biol Chem. 1984 Feb 25;259(4):2346–2354. [PubMed] [Google Scholar]
  27. Stiehm E. R., Kronenberg L. H., Rosenblatt H. M., Bryson Y., Merigan T. C. UCLA conference. Interferon: immunobiology and clinical significance. Ann Intern Med. 1982 Jan;96(1):80–93. doi: 10.7326/0003-4819-96-1-80. [DOI] [PubMed] [Google Scholar]
  28. Zoon K. C., Arnheiter H. Studies of the interferon receptors. Pharmacol Ther. 1984;24(2):259–278. doi: 10.1016/0163-7258(84)90037-8. [DOI] [PubMed] [Google Scholar]
  29. Zoon K. C., Arnheiter H., Zur Nedden D., Fitzgerald D. J., Willingham M. C. Human interferon alpha enters cells by receptor-mediated endocytosis. Virology. 1983 Oct 15;130(1):195–203. doi: 10.1016/0042-6822(83)90127-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES